Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P00966: Variant p.Arg157Cys

Argininosuccinate synthase
Gene: ASS1
Feedback?
Variant information Variant position: help 157 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Cysteine (C) at position 157 (R157C, p.Arg157Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CTLN1; decreased thermal stability; loss of argininosuccinate synthase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 157 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 412 The length of the canonical sequence.
Location on the sequence: help PQIKVIAPWRMPEFYNRFKG R NDLMEYAKQHGIPIPVTPKN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         PQIKVIAPWRMPEFYNRFKGRNDLMEYAKQHGIPIPVTPKN

Mouse                         PQIKVIAPWRMPEFYNRFKGRNDLMEYAKQHGIPIPVTPKS

Rat                           PQIKVIAPWRMPEFYNRFKGRNDLMEYAKQHGIPIPVTPKS

Bovine                        PQIKVIAPWRMPEFYNRFQGRNDLMEYAKQHGIPVPVTPKN

Chicken                       PSIKVIAPWRMPEFYQRFPGRRELMEYAQKHGIPVPVTPKA

Xenopus laevis                PEVKIIAPWRMPEFYNRFRGRSDLMEYAKKHNISVPVTPKS

Xenopus tropicalis            PEVKIIAPWRMPEFYNRFRGRSDLMEYAKKHNIPVPVTPKD

Zebrafish                     PQVQVIAPWRIPEFYNRFRGRKDLMEYAEKHNIPVPVTPKA

Drosophila                    PDLKIIAPWRDVEFCCQFQGRQDLIAYAQQHGIEVSAKPAT

Baker's yeast                 PDVKCITPWRMPEFFERFAGRKDLLDYAAQKGIPVAQTKAK

Fission yeast                 PDVQVIAPWRLPVFFERFAGRKDLLEYAAAKGIPVTQTTKK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 412 Argininosuccinate synthase
Modified residue 165 – 165 N6-acetyllysine; by CLOCK
Modified residue 176 – 176 N6-acetyllysine; by CLOCK
Mutagenesis 165 – 165 K -> QR. Significant loss of acetylation but no decrease in enzyme activity; when associated with Q-176 or R-176.
Mutagenesis 176 – 176 K -> QR. Significant loss of acetylation but no decrease in enzyme activity; when associated with Q-165 or R-165.



Literature citations
Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients.
Gao H.-Z.; Kobayashi K.; Tabata A.; Tsuge H.; Iijima M.; Yasuda T.; Kalkanoglu H.S.; Dursun A.; Tokatli A.; Coskun T.; Trefz F.K.; Skladal D.; Mandel H.; Seidel J.; Kodama S.; Shirane S.; Ichida T.; Makino S.; Yoshino M.; Kang J.-H.; Mizuguchi M.; Barshop B.A.; Fuchinoue S.; Seneca S.; Zeesman S.; Knerr I.; Rodes M.; Wasant P.; Yoshida I.; De Meirleir L.; Abdul-Jalil M.; Begum L.; Horiuchi M.; Katunuma N.; Nakagawa S.; Saheki T.;
Hum. Mutat. 22:24-34(2003)
Cited for: VARIANTS CTLN1 ARG-19; HIS-86; SER-95; SER-96; ASP-117; SER-117; CYS-157; ARG-179; LYS-191; HIS-265; MET-269; CYS-272; LYS-283; TRP-304; GLN-310; SER-324; VAL-362; GLN-363; TRP-363; ILE-389 AND ARG-390; Improved standards for prenatal diagnosis of citrullinemia.
Miller M.J.; Soler-Alfonso C.R.; Grund J.E.; Fang P.; Sun Q.; Elsea S.H.; Sutton V.R.;
Mol. Genet. Metab. 112:205-209(2014)
Cited for: VARIANTS CTLN1 PRO-91; CYS-157; ILE-180; LYS-283 AND ARG-390; VARIANT LEU-127; Kinetic mutations in argininosuccinate synthetase deficiency: characterisation and in vitro correction by substrate supplementation.
Diez-Fernandez C.; Wellauer O.; Gemperle C.; Ruefenacht V.; Fingerhut R.; Haeberle J.;
J. Med. Genet. 53:710-719(2016)
Cited for: VARIANTS CTLN1 PRO-91; LEU-96; SER-117; THR-118; ILE-119; ASN-124; CYS-157; HIS-157; CYS-272; HIS-272 AND LEU-272; CHARACTERIZATION OF VARIANTS CTLN1 PRO-91; SER-95; HIS-96; LEU-96; SER-96; SER-117; THR-118; ILE-119; ASN-124; GLN-127; TRP-127; CYS-157; HIS-157; ASN-180; ILE-180; GLN-191; GLN-270; CYS-272; HIS-272 AND LEU-272; CHARACTERIZATION OF VARIANT LEU-127; CATALYTIC ACTIVITY; PATHWAY; FUNCTION; SUBCELLULAR LOCATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.